The Link Between EBV and Lymphoma: A Causal Connection

Epstein-Barr virus is causally connected to several types of lymphoma, not just loosely associated with them. The virus was, in fact, the first human virus linked to cancer, and decades of molecular, epidemiological, and experimental evidence have since clarified how it drives lymphoma development across at least four major subtypes. Yet the relationship is not straightforward: more than 90 percent of adults worldwide carry EBV, while only a small fraction develop an EBV-related cancer. Understanding why requires a closer look at how the virus behaves inside the body and what additional conditions tip the balance toward malignancy.

How EBV Was First Linked to Cancer

In 1964, researchers identified a new herpesvirus in cultured tumor cells from a Burkitt lymphoma biopsy taken from an African patient.¹ That discovery, made by Anthony Epstein and Yvonne Barr, opened a new field of tumor virology. Before that point, the idea that a virus could cause cancer in humans was speculative at best. In the decades that followed, EBV turned up in other cancers too, including Hodgkin lymphoma, certain aggressive B-cell and NK/T-cell lymphomas, nasopharyngeal carcinoma, and some gastric cancers. But the lymphoma connection remains the most thoroughly studied and the most clearly causal.

How EBV Persists in the Body

EBV is a herpesvirus, and like all herpesviruses, it establishes a lifelong infection. After the initial exposure, which usually happens in childhood or adolescence, the virus takes up residence in B cells, a type of white blood cell central to the immune system. What makes EBV particularly cunning is the way it exploits the natural life cycle of these cells to hide from immune detection.

In the tonsils, newly infected B cells express a broad set of viral genes that drive the cells to multiply. As those B cells mature and move into the germinal centers of lymph nodes, EBV dials back its gene expression to a more restricted pattern. By the time the infected cells become long-lived memory B cells circulating in the blood, the virus goes nearly silent, expressing little to no protein at all.² This stepwise retreat is not random. It mirrors the normal differentiation of B cells, allowing EBV to piggyback on the body’s own biology and persist indefinitely in the memory B cell compartment.

Researchers have classified these different states into latency programs, numbered 0 through III, each defined by which viral genes are active.³ The specific latency program a tumor cell uses turns out to be a signature of the lymphoma subtype it gives rise to, which is why the biology of EBV latency matters for understanding the cancer connection.

Burkitt Lymphoma and the Myc Partnership

Burkitt lymphoma is one of the fastest-growing human cancers. Its hallmark is a chromosomal rearrangement that switches on the Myc gene, a powerful driver of cell growth and division, by placing it next to an immunoglobulin gene region. But activated Myc does not just make cells proliferate. It also triggers built-in safety mechanisms: cells with an abnormally active oncogene tend to self-destruct through programmed cell death, or they stop dividing permanently. For a tumor to form, those safety brakes have to fail.

This is where EBV comes in. In endemic Burkitt lymphoma, the form found predominantly in equatorial Africa, more than 95 percent of tumors carry latent EBV. The virus’s gene products can block the cell-death and growth-arrest pathways that Myc would otherwise trigger, effectively removing the fail-safe and letting Myc-driven proliferation proceed unchecked.⁴ EBV does not cause the Myc translocation itself; rather, it rescues cells that would otherwise die from its consequences. The virus is a necessary accomplice, not the sole instigator.

A striking feature of endemic Burkitt lymphoma is its geographic overlap with regions where malaria caused by Plasmodium falciparum is common. This is not coincidence. Chronic malaria exposure reshapes the immune landscape through sustained inflammation, altered immune cell function, and weakened immune surveillance. These changes may help EBV persist more aggressively in B cells and increase the chances of the genomic instability that leads to Myc translocations.⁵ The interplay between the parasite and the virus is a textbook example of how co-infections compound cancer risk.

Hodgkin Lymphoma

About 30 to 50 percent of Hodgkin lymphoma cases in Western countries are EBV-positive, with higher rates in lower-income regions and in younger children. The malignant cells in Hodgkin lymphoma, known as Reed-Sternberg cells, are unusual: they are derived from B cells that have lost much of their B-cell identity yet survive and proliferate in an inflammatory environment. In EBV-positive cases, the virus appears to provide the survival signals these abnormal cells need.

One key viral protein, LMP1, mimics a constitutively active growth receptor. It switches on signaling pathways that promote cell survival and help the tumor evade the immune system. In Hodgkin lymphoma tissue, LMP1 has been shown to induce expression of CD137 on the surface of Reed-Sternberg cells, with 96 percent of CD137-positive Hodgkin lymphoma cases also staining positive for LMP1.⁶ CD137 on these cells supports their growth and helps them dodge immune attack. In EBV-negative Hodgkin lymphoma, other mutations apparently fill the same functional role that EBV plays in positive cases, which is why the disease can arise with or without the virus.

Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma in adults. EBV-positive DLBCL was formally recognized as a distinct entity in the WHO classification of lymphoid tumors in 2016.⁷ It tends to be more aggressive than its EBV-negative counterpart and is more common in older adults, particularly those with age-related immune decline.

Molecular profiling of EBV-positive DLBCL shows that it does not fit neatly into the standard genetic subtypes used to classify DLBCL overall. In one study, over 80 percent of EBV-positive cases could not be assigned to any recognized molecular subgroup, suggesting that the virus drives the disease through mechanisms distinct from the usual mutational pathways.⁸ This finding has practical implications: treatments designed around the standard molecular subtypes may not work as well for EBV-driven cases, and identifying the virus’s presence at diagnosis matters for prognosis and treatment planning.

NK/T-Cell Lymphomas

EBV does not only cause B-cell cancers. Extranodal NK/T-cell lymphoma, nasal type, is considered the prototype of an EBV-driven lymphoma arising from natural killer cells or T cells rather than B cells. This aggressive cancer occurs predominantly in Asia and Latin America and is almost universally EBV-positive.⁹ The viral contribution here involves activating growth-promoting signaling pathways and helping tumor cells evade immune destruction, with recurrent mutations in pathways like JAK-STAT compounding the viral effects.

A related condition called chronic active EBV disease can precede NK/T-cell lymphoma. In this disorder, EBV infects T cells or NK cells rather than B cells, causing persistent inflammation and tissue damage. In some patients, the disease progresses to overt lymphoma.¹⁰ Research into this progression has found that virus-dependent, non-genetic mechanisms contribute to disease, since chronic active EBV disease and NK/T-cell lymphoma lack a common genetic driver mutation.¹¹ The virus itself appears to be doing most of the heavy lifting through epigenetic changes and chromatin reorganization rather than through accumulated DNA mutations.

When the Immune System Breaks Down

The clearest evidence that EBV is a direct driver of lymphoma comes from situations where immune surveillance collapses. In healthy people, EBV-infected B cells are kept in check by T cells that recognize and kill them. Remove that surveillance, and the virus-infected cells can proliferate unchecked.

Patients who receive organ transplants or bone marrow transplants and take immunosuppressive drugs are at risk of post-transplant lymphoproliferative disorders. These range from benign-looking expansions of EBV-infected B cells to frank lymphomas, and they arise because the drugs suppress the very T cells that normally control EBV.¹² The fact that reducing immunosuppression sometimes allows these growths to regress on their own is strong evidence that the immune system is the main brake on EBV-driven lymphomagenesis.

HIV presents a parallel scenario. The incidence of lymphomas is sharply increased in people living with HIV, and the prevalence of EBV in these lymphomas is high.¹³ In one study, EBV was detected in about two-thirds of HIV-related lymphoma cases compared with only 5 percent of non-HIV-related lymphomas.¹⁴ That thirteen-fold difference underscores how much immune control matters. When the immune system can no longer keep EBV in check, the virus’s oncogenic potential is unleashed.

The Molecular Toolkit EBV Uses to Promote Cancer

EBV does not cause lymphoma simply by being present. It actively manipulates host cells through several molecular strategies that work in concert.

The viral protein LMP1 is the most studied of these tools. It activates a signaling pathway called NF-κB, which promotes cell survival. Through this pathway, LMP1 increases the breakdown of p53, a critical tumor-suppressor protein, and boosts production of anti-death proteins like Bcl-2.¹⁵ The net effect is a cell that resists dying even when it accumulates the kind of damage that would normally trigger self-destruction.

Beyond its proteins, EBV produces small non-coding RNA molecules, including viral microRNAs, that help the virus persist in its host and contribute to cancer development.¹⁶ These molecules can silence host genes involved in immune detection or cell-death pathways without the virus needing to produce any protein at all, making them harder for the immune system to spot.

EBV also functions as an epigenetic manipulator, reprogramming cells in ways that leave long-lasting, cancer-promoting changes to gene activity even after the viral genes themselves are no longer expressed.¹⁷ These alterations affect how the host cell reads its own DNA, locking in growth-promoting patterns that persist across cell divisions. It is a kind of cellular reprogramming that does not require mutations in the DNA sequence itself.

Layered on top of all this, EBV has evolved strategies to interfere with both innate and adaptive immunity, helping infected cells avoid detection.¹⁸ Viral proteins and non-coding RNAs both participate in this immune evasion.¹⁹ The result is a virus that can keep infected cells alive, proliferating, and invisible to the immune system simultaneously.

How Doctors Detect EBV in Lymphoma Tissue

Knowing whether a lymphoma is EBV-positive changes how it is classified, what prognosis the patient receives, and increasingly, what treatments are considered. The standard method is a laboratory test called EBER in situ hybridization. EBV-infected cells contain large numbers of small RNA molecules called EBERs, and a probe that binds specifically to these molecules will light up the nuclei of infected cells in a tissue biopsy.²⁰ Because each infected cell contains so many copies of these RNAs, the test is sensitive and reliable.

However, EBER testing has limits. Measuring the actual amount of EBV DNA in a tumor specimen can provide additional clinical information beyond what EBER status alone reveals. In one study of DLBCL patients, EBV DNA was detected in up to 72 percent of cases classified as EBER-negative, suggesting that low-level EBV involvement may be more common than the standard test indicates.²¹ Whether that low-level viral DNA is biologically meaningful or an incidental bystander remains an open question, but it hints that the binary “EBV-positive or negative” classification may oversimplify the situation.

Therapies That Target the EBV Connection

If EBV is driving a lymphoma, then restoring or supplementing the immune response against the virus becomes a logical treatment strategy. Several groups have developed EBV-specific T cell therapies in which T cells trained to recognize EBV-infected cells are grown in the lab and infused into the patient.

For transplant recipients who develop EBV-driven lymphomas that do not respond to standard treatment, off-the-shelf EBV-specific T cells from partially matched donors have shown promising results. In one trial, complete or sustained partial remission was achieved in 68 percent of bone marrow transplant recipients and 54 percent of organ transplant recipients, and one-year survival was around 89 percent for those who responded.²² Patients who did not respond to a first infusion sometimes responded when given T cells from a different donor, suggesting that matching matters.

For NK/T-cell lymphoma, autologous EBV-specific T cells (made from the patient’s own blood) have also shown activity. In a multicenter study of patients with relapsed or treatment-resistant disease, the overall response rate was 50 percent and the treatment was well tolerated.²³ These are early-phase results in hard-to-treat patients, but they validate the principle that going after EBV directly can control the cancers it drives.

The Long Road to an EBV Vaccine

If nearly all adults carry EBV and a small but meaningful fraction of EBV-associated cancers arise as a result, preventing infection in the first place would be a major public health win. Vaccine research has been underway for decades, targeting EBV envelope proteins like gp350 and viral latency genes. But a licensed vaccine remains elusive.²⁴

The difficulty lies partly in the complexity of the EBV life cycle, which involves multiple cell types and stages that would each need to be addressed. The virus infects epithelial cells in the throat and B cells in the blood, using different molecular entry points for each. Additionally, establishing that a vaccine prevents cancer requires long follow-up in large populations, since the cancers take years or decades to develop. Newer mRNA-based vaccine platforms and nanoparticle delivery systems are currently in clinical trials, building on the technological advances that came out of COVID-19 vaccine development. Whether these will finally crack the problem is still an open question, but there is more momentum in EBV vaccine research now than at any previous point.

The Global Health Burden

EBV-attributable cancers are not a niche concern. A global analysis covering 1990 to 2017 found that EBV contributed to over 265,000 incident cancer cases and about 164,000 deaths annually across four major cancer types, including lymphomas and nasopharyngeal and gastric carcinomas.²⁵ Over that 27-year period, the burden of mortality from these cancers increased by about 19 percent. A separate economic analysis estimated that EBV-related cancer mortality adds roughly $32 billion to the global burden.²⁶

These numbers help explain why both vaccine research and EBV-targeted therapies attract serious funding and attention. A virus carried by more than nine in ten adults that contributes to hundreds of thousands of cancers each year represents one of the larger modifiable causes of cancer mortality worldwide. The fact that the link is causal, not merely correlational, means that interventions targeting the virus itself have a realistic chance of reducing the cancer toll.

Host Genetics and Viral Diversity

Not everyone who carries EBV faces the same cancer risk, and part of the explanation is genetic. A large study examining the interaction between human genetic variation and EBV sequence diversity found significant associations between specific human genetic variants and particular EBV strains. For example, one human genetic variant near the gene UNC5D was linked to variation in the EBV gene BALF5, with an odds ratio of about 1.3, and multiple variants on chromosome 7 were associated with a specific amino acid change in the EBV gene BRLF1, with an odds ratio of roughly 1.4.²⁷ These findings suggest that the host’s genetic makeup influences which EBV strains take hold, and potentially which strains are more dangerous. The research is still in its early stages, but it points toward a future where someone’s genetic background could help predict their EBV-related cancer risk, adding a personalized dimension to what has so far been a population-level story.